NCT02450513View on ClinicalTrials.gov

Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

May 25, 2016

Study Completion Date

May 25, 2016

Conditions
Crohn's Disease
Interventions
DRUG

Adalimumab

160 mg at week 0, 80 mg at week 2 and 40 mg every two weeks onwards

Trial Locations (2)

3000

University Hospitals Leuven, Leuven

8800

AZ Delta, Roeselare

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT02450513 - Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study | Biotech Hunter | Biotech Hunter